Misonix (NASDAQ:MSON) posted its quarterly earnings results on Thursday. The medical equipment provider reported $0.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.34, Fidelity Earnings reports. The business had revenue of $11.15 million during the quarter. Misonix had a negative net margin of 19.01% and a negative return on equity of 25.99%.
Shares of MSON traded up $2.87 during mid-day trading on Friday, reaching $19.62. The stock had a trading volume of 103,600 shares, compared to its average volume of 43,956. Misonix has a 12 month low of $13.87 and a 12 month high of $27.54. The business has a fifty day moving average of $18.09 and a 200 day moving average of $20.76.
MSON has been the subject of a number of recent analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $30.00 price target (up from $24.00) on shares of Misonix in a research report on Thursday, August 15th. ValuEngine lowered shares of Misonix from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, BTIG Research reiterated a “buy” rating and issued a $27.00 price target on shares of Misonix in a research report on Thursday, August 15th. One research analyst has rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Misonix has a consensus rating of “Buy” and a consensus price target of $28.50.
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
See Also: Back-End Load
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.